Ticagrelor is a drug with antiplatelet effect, circulated in Vietnam under the brand name Brilinta. In the fourth quarter of 2020, the US Food and Drug Administration (FDA) approved Brilinta to be prescribed for the purpose of reducing the risk of stroke in patients with ischemic stroke (with NISSH score <=5) or stroke. high-risk transient ischemic attack.